“Genital herpes - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Genital herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Genital herpes Understanding
Genital herpes: Overview Genital herpes is a sexually transmitted infection (STI) that causes blisters and ulcers. Herpes is caused by the herpes simplex virus (HSV), which is transmitted through skin-to-skin contact. Herpes can affect various areas of the body but is most commonly found on the genitals, anus or mouth. The blisters heal with time (usually within 2-3 weeks), but the virus that causes them cannot be cured, and herpes outbreaks will often reoccur. Genital herpes can be treated and managed. Baill stresses that for most people who have healthy immune systems, the high-risk times for giving a sex partner genital herpes are during the first outbreak and during later outbreaks of sores.
"Genital herpes - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital herpes pipeline landscape is provided which includes the disease overview and Genital herpes treatment guidelines. The assessment part of the report embraces, in depth Genital herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Genital herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital herpes.
Genital herpes Emerging Drugs Chapters This segment of the Genital herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital herpes Emerging Drugs • Pritelivir (AIC316): AiCuris
Pritelivir is a new small molecule, a helicase-primase inhibitor with a novel mode of action. In a phase 2 study conducted earlier for suppressive treatment, oral pritelivir showed to significantly improve the suppression of viral shedding compared to the current standard of care for genital HSV-2 infections, the nucleoside analog valacyclovir. Currently, it is in phase III stage of development to treat genital herpes.
Further product details are provided in the report……..
Genital herpes: Therapeutic Assessment This segment of the report provides insights about the different Genital herpes drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Genital herpes
There are approx. 20+ key companies which are developing the therapies for Genital herpes. The companies which have their Genital herpes drug candidates in the most advanced stage, i.e. phase III include, AiCuris.
This report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Genital herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Genital herpes: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital herpes drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Genital herpes drugs?
• How many Genital herpes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital herpes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital herpes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Genital herpes and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players • United Biopharma
• Rational Vaccines
• BlueWillow Biologics
• Heidelberg ImmunoTherapeutics
• EXCELL BIOTECH
• AlphaVax, Inc.
• NANOVIRICIDES, INC.
• Vaccibody AS
• Vaxart, Inc.
• Beech Tree Labs
• Rational Vaccines
• Auro Vaccines
• Redbiotec AG
120 pages •
By Infiniti Research Limited
• Jul 2021
Global Clostridium Difficile Treatment Market 2021-2025 The analyst has been monitoring the Clostridium difficile treatment market and it is poised to grow by $ 253.54 mn during 2021-2025, progressing at a CAGR of about 5% during the forecast period. Our report on Clostridium difficile treatment market provides a holistic...
“Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...
Rhabdomyosarcoma (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Drugs In Development, 2021, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape. Rhabdomyosarcoma (RMS) is a malignant...
Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2021 Summary Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded by the GABRA3 gene. GABRA3 are ligand-gated...
The global wearable injectors market is projected to reach USD 11.5billion by 2026 from USD 7.2billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various...
The anaphylaxis treatment market in Europe is expected to grow from US$ 534.0 million in 2021 to US$ 987.2 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. Anaphylaxis is a severe, life?threatening allergic reaction caused by vulnerability to allergens (foods, insect stings, or medicines) identified as a...
“Glioblastoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 184.108.40.206) - Drugs In Development, 2021 Summary Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 220.127.116.11) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining...
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 18.104.22.168) - Drugs In Development, 2021 Summary Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 22.214.171.124) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin...
Report Scope: This report is an analytical business tool with the primary purpose of providing a thorough evaluation of the global market for mRNA therapeutics for the prevention of infectious diseases (through prophylactic vaccines) and treatment of chronic (e.g., cancer, heart diseases) and several other rare diseases. The...
Infectious Disease Incidence
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.